来自 ReIMAGINE 前列腺癌风险研究的最新进展（NCT04060589）：这是一项前瞻性队列研究，纳入了疑似前列腺癌并被转至基于磁共振成像的诊断途径的男性，他们捐赠了组织、血液和尿液以进行生物标志物分析。
An update from the ReIMAGINE Prostate Cancer Risk Study (NCT04060589): A prospective cohort study in men with a suspicion of prostate cancer who are referred onto a magnetic resonance imaging-based diagnostic pathway with donation of tissue, blood, and urine for biomarker analyses.
机构信息
UCL Division of Targeted Intervention, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK; Imperial Urology, Imperial College Healthcare NHS Trust, London, UK.
出版信息
Eur Urol. 2021 Oct;80(4):398-399. doi: 10.1016/j.eururo.2021.06.011. Epub 2021 Jul 1.
ReIMAGINE represents the first efforts to define prostate cancer risk using the full spectrum of emerging diagnostics (both commercial and academic). The outputs will provide image-based data sets that will replace, or adjust, historical and flawed risk calculators.
ReIMAGINE 代表了首次利用新兴诊断技术（包括商业和学术）全面定义前列腺癌风险的努力。其结果将提供基于图像的数据集，以取代或调整有缺陷的历史风险计算器。
Zotero 插件